Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,763
archived clinical trials in
Colitis

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
630
mi
from
Milwaukee, WI
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
630
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated:  12/31/1969
1321
mi
from
Edmonton,
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated: 12/31/1969
1321
mi
from
Edmonton,
Click here to add this to my saved trials
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
409
mi
from
Denver, CO
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
409
mi
from
Denver, CO
Click here to add this to my saved trials
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1114
mi
from
Fairfax, VA
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1114
mi
from
Fairfax, VA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
683
mi
from
Birmingham, AL
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
805
mi
from
Decatur, GA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
805
mi
from
Decatur, GA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
657
mi
from
Louisville, KY
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
657
mi
from
Louisville, KY
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
808
mi
from
Ann Arbor, MI
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
515
mi
from
Rochester, MN
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
515
mi
from
Rochester, MN
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1383
mi
from
Portland, OR
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1383
mi
from
Portland, OR
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
630
mi
from
Milwaukee, WI
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
630
mi
from
Milwaukee, WI
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1143
mi
from
San Diego, CA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1143
mi
from
San Diego, CA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1339
mi
from
San Francisco, CA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1339
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
420
mi
from
Lafayette, CO
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
420
mi
from
Lafayette, CO
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
407
mi
from
Littleton, CO
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
407
mi
from
Littleton, CO
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
411
mi
from
Thornton, CO
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
411
mi
from
Thornton, CO
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1345
mi
from
Hamden, CT
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1345
mi
from
Hamden, CT
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1053
mi
from
Jacksonville, FL
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1053
mi
from
Jacksonville, FL
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1320
mi
from
Miami, FL
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1320
mi
from
Miami, FL
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1140
mi
from
Winter Park, FL
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1140
mi
from
Winter Park, FL
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
801
mi
from
Atlanta, GA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
871
mi
from
Macon, GA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
871
mi
from
Macon, GA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
144
mi
from
Topeka, KA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
144
mi
from
Topeka, KA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
637
mi
from
Baton Rouge, LA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
637
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1123
mi
from
Chevy Chase, MD
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1123
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
843
mi
from
Troy, MI
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
843
mi
from
Troy, MI
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
1063
mi
from
Cheektowaga, NY
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
1063
mi
from
Cheektowaga, NY
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
959
mi
from
Charlotte, NC
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
959
mi
from
Charlotte, NC
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
941
mi
from
Elkin, NC
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
941
mi
from
Elkin, NC
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
481
mi
from
Germantown, TN
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
481
mi
from
Germantown, TN
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
583
mi
from
San Antonio, TX
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
583
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
398
mi
from
Tyler, TX
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
398
mi
from
Tyler, TX
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1053
mi
from
Charlottesville, VA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1053
mi
from
Charlottesville, VA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1111
mi
from
Richmond, VA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1111
mi
from
Richmond, VA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Research Site
9338
mi
from
Adelaide,
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Research Site
9338
mi
from
Adelaide,
Click here to add this to my saved trials
Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy
Early Supplementation of Enteral Lipid With Combination of Microlipid and Fish Oil in Infants With Enterostomy
Status: Enrolling
Updated:  12/31/1969
WFUHS Brenner Children's Hospital NICU
974
mi
from
Winston-Salem, NC
Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy
Early Supplementation of Enteral Lipid With Combination of Microlipid and Fish Oil in Infants With Enterostomy
Status: Enrolling
Updated: 12/31/1969
WFUHS Brenner Children's Hospital NICU
974
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Oral OKT3 for the Treatment of Active Ulcerative Colitis
Oral Anti-CD3 for the Treatment of Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
1444
mi
from
Boston, MA
Oral OKT3 for the Treatment of Active Ulcerative Colitis
Oral Anti-CD3 for the Treatment of Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
Click here to add this to my saved trials
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
1177
mi
from
Los Angeles, CA
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated:  12/31/1969
Stanford University
1329
mi
from
Palo Alto, CA
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated: 12/31/1969
Stanford University
1329
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated:  12/31/1969
Yale University
1344
mi
from
New Haven, CT
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated: 12/31/1969
Yale University
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated:  12/31/1969
Emory University
801
mi
from
Atlanta, GA
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated: 12/31/1969
Emory University
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated:  12/31/1969
Indiana University
642
mi
from
Indianapolis, IN
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated: 12/31/1969
Indiana University
642
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated:  12/31/1969
University of Iowa
428
mi
from
Iowa City, IA
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated: 12/31/1969
University of Iowa
428
mi
from
Iowa City, IA
Click here to add this to my saved trials
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
1443
mi
from
Boston, MA
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated:  12/31/1969
Wayne State University
841
mi
from
Detroit, MI
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated: 12/31/1969
Wayne State University
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospital
198
mi
from
Kansas City, MO
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospital
198
mi
from
Kansas City, MO
Click here to add this to my saved trials
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated:  12/31/1969
University of New Mexico
526
mi
from
Albuquerque, NM
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated: 12/31/1969
University of New Mexico
526
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated:  12/31/1969
University of Rochester
1121
mi
from
Rochester, NY
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age
Status: Enrolling
Updated: 12/31/1969
University of Rochester
1121
mi
from
Rochester, NY
Click here to add this to my saved trials